Study of Mantle Cell Lymphoma Treatment by RiBVD

Demonstration of Improvement of progression-free survival (PFS) compared to literature data. 6 months prolongation equal 24 months compared to 18 months obtained whatever the current regimen and in particular compared to RCHOP regimen

Inclusion criteria

• mantle cell Lymphoma CD20 positive
• Untreated patients
• 65 ans years old patients or 18 to 65 years old patients who can't or refuse receive conditioning regimen followed by autograft.
• Stages Ann Arbor II, III or IV,
• ECOG performance status of 0, 1 or 2
• Without history of neoplasm, except in situ cervix carcinoma and cutaneous basal cell epithelioma, or in complete remission since 3 years,
• Without drug contraindication used in the schema (Rituximab, benda-mustine, Velcade, Dexamethasone),
• Without heart insufficiency or stabilized,
• With the following biological values limits except if pathological values are due to Medullary invading or hypersplenism, hepatic involvement) :PNN more than 1 G/L, Platelets more than 50 G/L,Transaminases (SGOT and SGPT) and alkalin phosphatases alcalines less than 4 x normal,Bilirubin less than 3 x N,- Clearance creatinemia more than 20 mL/min
• Hepatitis B negative serology unless the seropositivity is clearly linked to a vaccination.
• Can be regularly followed
• Who signed the informed consent,
• Affiliated to a national insurance or such a same scheme .

Exclusion criteria

• Other type of lymphoma than mantle cell lymphoma according to OMS 2008 classification
• Patients in relapse, except those in relapse due to localized stade who only received locoregional irradiation or splenectomized,
• Central nervous system localization in particular meninge,
• Drug used in the schema contraindication Rituximab , Bendamustine , Velcade® or Dexamethasone
• Non stable diabetes,
• HIV positive or active hepatitis C or B
• ECOG performance status equal or more than 3
• Peripheral neuropathy, whatever its origin, rated more than 2 from NCI
• Non stabilized heart insufficiency,
• Patient who can't receive hyperhydration in order to treat tumoral lysis syndrome or in prophylaxis,
• Patient who can't, whatever the reason, be regularly followed,
• Major patient who are on legal protection, or can't give their consent
• Patient who has not signed the informed consent